Comparing biomarker results in resected melanoma in RELATIVITY-098 and advanced melanoma in RELATIVITY-047 suggested that the presence of tumor and associated higher levels of LAG-3+ T cells in the blood may be necessary to derive additional clinical benefit with nivolumab plus relatlimab over nivolumab. Here, LAG3 is linked to neoplasm.